{"id":"neoadjuvant-chemotherapy-folfirinox-4-cycles","safety":{"commonSideEffects":[{"rate":"75-80","effect":"Neutropenia"},{"rate":"70-75","effect":"Anemia"},{"rate":"65-70","effect":"Thrombocytopenia"},{"rate":"55-60","effect":"Diarrhea"},{"rate":"80-85","effect":"Nausea/vomiting"},{"rate":"40-50","effect":"Peripheral neuropathy"},{"rate":"60-70","effect":"Fatigue"},{"rate":"35-45","effect":"Mucositis"},{"rate":"15-25","effect":"Febrile neutropenia"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFIRINOX combines four cytotoxic agents (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) that work synergistically to kill rapidly dividing cancer cells. Fluorouracil and leucovorin disrupt nucleotide synthesis and DNA replication, irinotecan prevents DNA topoisomerase I-mediated DNA unwinding, and oxaliplatin creates DNA cross-links. This multi-agent approach provides broader cytotoxic coverage and is used in the neoadjuvant setting to shrink tumors before surgical resection.","oneSentence":"FOLFIRINOX is a combination chemotherapy regimen that simultaneously attacks cancer cells through multiple mechanisms: fluorouracil and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis, while irinotecan inhibits topoisomerase I to prevent DNA unwinding.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:47.894Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neoadjuvant treatment of locally advanced pancreatic cancer"},{"name":"Metastatic colorectal cancer"},{"name":"Gastric and gastroesophageal junction adenocarcinoma"}]},"trialDetails":[{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT06122480","phase":"NA","title":"Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-05-21","conditions":"Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease","enrollment":5},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT02959879","phase":"PHASE2","title":"Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-03-01","conditions":"Resectable Pancreatic Duct Adenocarcinoma","enrollment":153},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT07043270","phase":"PHASE2","title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-09-29","conditions":"Pancreas Adenocarcinoma","enrollment":35},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT04594772","phase":"PHASE2","title":"Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2021-03-17","conditions":"Pancreas Cancer","enrollment":32},{"nctId":"NCT01804790","phase":"PHASE3","title":"Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Cancer of the Rectum","enrollment":461},{"nctId":"NCT01821612","phase":"EARLY_PHASE1","title":"Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2013-05-29","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":23},{"nctId":"NCT05121038","phase":"PHASE1, PHASE2","title":"CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anup Kasi","startDate":"2021-10-20","conditions":"Colon Cancer, Pancreas Cancer, Digestive Cancer","enrollment":50},{"nctId":"NCT06714604","phase":"PHASE3","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","status":"RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2023-10-18","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer","enrollment":432},{"nctId":"NCT05462496","phase":"PHASE2","title":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-03-16","conditions":"Pancreatic Cancer","enrollment":25},{"nctId":"NCT04927780","phase":"PHASE3","title":"Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2021-09-07","conditions":"Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":378},{"nctId":"NCT02514278","phase":"PHASE3","title":"Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-01-28","conditions":"Rectal Cancer","enrollment":218},{"nctId":"NCT05081687","phase":"PHASE3","title":"Brazilian Total Neoadjuvant Therapy Trial","status":"UNKNOWN","sponsor":"Hospital Israelita Albert Einstein","startDate":"2020-02-20","conditions":"Colorectal Neoplasms","enrollment":150},{"nctId":"NCT03099265","phase":"PHASE2","title":"Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-06-26","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT05399394","phase":"PHASE2","title":"Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Campus Bio-Medico University","startDate":"2016-07-01","conditions":"Pancreatic Cancer","enrollment":50},{"nctId":"NCT04617821","phase":"PHASE3","title":"AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-09-01","conditions":"Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma","enrollment":300},{"nctId":"NCT01660711","phase":"PHASE2","title":"A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2012-07","conditions":"Pancreatic Adenocarcinoma","enrollment":22},{"nctId":"NCT04835064","phase":"PHASE3","title":"Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-04-01","conditions":"Pancreatic Adenocarcinoma","enrollment":600},{"nctId":"NCT03600623","phase":"EARLY_PHASE1","title":"Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2017-09-25","conditions":"Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer","enrollment":25},{"nctId":"NCT02749136","phase":"PHASE2","title":"Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2016-05","conditions":"Pancreatic Adenocarcinoma","enrollment":44},{"nctId":"NCT01992705","phase":"EARLY_PHASE1","title":"Borderline Pancreas Study: FOLFIRINOX +SBRT","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2014-03","conditions":"Resectable Pancreatic Cancer","enrollment":8},{"nctId":"NCT02548169","phase":"PHASE1","title":"Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Baylor Research Institute","startDate":"2015-08","conditions":"Pancreatic Cancer","enrollment":7},{"nctId":"NCT01359007","phase":"PHASE2","title":"FOLFIRINOX in Patients With Inoperable Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Oklahoma","startDate":"2011-05","conditions":"Adenocarcinoma of Pancreas","enrollment":5},{"nctId":"NCT01446458","phase":"PHASE1","title":"Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-11","conditions":"Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic","enrollment":13},{"nctId":"NCT01760694","phase":"NA","title":"Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Southwestern Regional Medical Center","startDate":"2013-01","conditions":"Pancreatic Cancer","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Neoadjuvant chemotherapy Folfirinox, 4 cycles","genericName":"Neoadjuvant chemotherapy Folfirinox, 4 cycles","companyName":"University Hospital, Bordeaux","companyId":"university-hospital-bordeaux","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFIRINOX is a combination chemotherapy regimen that simultaneously attacks cancer cells through multiple mechanisms: fluorouracil and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis, while irinotecan inhibits topoisomerase I to prevent DNA unwinding. Used for Neoadjuvant treatment of locally advanced pancreatic cancer, Metastatic colorectal cancer, Gastric and gastroesophageal junction adenocarcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}